Deutsche Bank AG Reaffirms “Buy” Rating for AstraZeneca plc (AZN)

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. They currently have a GBX 5,600 ($73.63) target price on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price points to a potential upside of 8.36% from the stock’s previous close.

A number of other analysts have also commented on the company. UBS AG set a GBX 4,550 ($59.82) price target on AstraZeneca plc and gave the company a “neutral” rating in a research note on Monday. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Monday. HSBC Holdings plc lifted their price target on AstraZeneca plc from GBX 4,100 ($53.90) to GBX 4,150 ($54.56) and gave the company a “reduce” rating in a research note on Monday. Barclays PLC reissued an “overweight” rating and set a GBX 6,300 ($82.83) price target on shares of AstraZeneca plc in a research note on Thursday, October 5th. Finally, BNP Paribas set a GBX 5,800 ($76.26) price target on AstraZeneca plc and gave the company a “buy” rating in a research note on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 5,113.55 ($67.23).

Shares of AstraZeneca plc (LON AZN) opened at 5168.00 on Wednesday. The company’s market capitalization is GBX 65.43 billion. The firm’s 50-day moving average price is GBX 4,786.58 and its 200 day moving average price is GBX 4,901.67. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.

ILLEGAL ACTIVITY WARNING: This article was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/10/11/deutsche-bank-ag-reaffirms-buy-rating-for-astrazeneca-plc-azn-2.html.

In related news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($57.45) per share, with a total value of £1,704.30 ($2,240.73).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply